DOCSLIB.ORG

Single Report Database for Drug-Induced Thrombocytopenia: an Update 2018 for Definitions of Bleeding, Score and Inclusion/Exclusion Criteria, Click Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Single Report Database for Drug-Induced Thrombocytopenia: An Update 2018 For definitions of bleeding, score and inclusion/exclusion criteria, click here. HOS = Hospitalized, BL = Bleeding, SC = Score, EX = Exclusion, NR = Not Recorded, NA = Not Applicable DRUG NAME CITATION YEAR AGE SEX DEATH HOS BL SC EX NEW 2018 ABCIXIMAB AM J CARDIOL 78:1161-1163 1996 64 YRS M NR YES 3 2 NA NO ABCIXIMAB AM J CARDIOL 78:1161-1163 1996 70 YRS M NR YES 2 3 NA NO ABCIXIMAB AM J CARDIOL 78:1161-1163 1996 42 YRS M NR YES 2 3 NA NO ABCIXIMAB AM J CARDIOL 78:1161-1163 1996 59 YRS F NR YES 3 3 NA NO ABCIXIMAB CIRCULATION 95:809-813 1997 53 YRS M NR NO NR 3 NA NO ABCIXIMAB CIRCULATION 95:809-813 1997 49 YRS F NR NO NR 3 NA NO ABCIXIMAB CIRCULATION 95:809-813 1997 83 YRS M NR NO NR 3 NA NO ABCIXIMAB CIRCULATION 95:809-813 1997 62 YRS M NR NO NR 3 NA NO ABCIXIMAB CIRCULATION 96:3809-3810 1997 NR M NR NO NR 5 1 NO ABCIXIMAB CIRCULATION 96:3809-3810 1997 NR F NR NO NR 5 1 NO ABCIXIMAB CIRCULATION 96:3809-3810 1997 NR M NR NO NR 5 1 NO ABCIXIMAB CIRCULATION 97:1214-1215 1998 62 YRS M NO YES NR 3 NA NO ABCIXIMAB CLIN CARDIOL 21:851-852 1998 82 YRS M NO YES NR 3 NA NO ABCIXIMAB LANCET 352:1312 1998 63 YRS M NO YES NR 3 NA NO ABCIXIMAB J AM COLL CARDIOL 32:311-319 1998 NR NR NR NO NR 5 1 NO ABCIXIMAB AM J HEMATOL 61:205-208 1999 55 YRS M NR NO NR 3 NA NO ABCIXIMAB AM J HEMATOL 61:205-208 1999 51 YRS M NR NO NR 3 NA NO ABCIXIMAB AM J HEMATOL 61:205-208 1999 48 YRS M NR NO NR 3 NA NO ABCIXIMAB J INVASIVE CARDIOL 11:313-315 1999 75 YRS M NR NO NR 3 NA NO ABCIXIMAB LANCET 353: 1185 1999 63 YRS F NR NR NR 5 2 NO ABCIXIMAB J INVASIVE CARDIOL 12:109-112 2000 52 YRS M NO YES 0 2 NA NO ABCIXIMAB J INVASIVE CARDIOL 12:528 2000 80 YRS F NO YES 0 2 NA NO ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO DRUG NAME CITATION YEAR AGE SEX DEATH HOS BL SC EX NEW 2018 ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO ABCIXIMAB AM J CARDIOL 85:435 2000 NR NR NR NO NR 3 NA NO ABCIXIMAB HEART 83:E5 2000 64 YRS M NO YES 0 3 NA NO ABCIXIMAB N Z MED J 113:86 2000 56 YRS M NR NO NR 3 NA NO ABCIXIMAB ANN PHARMACOTHER 34:924 2000 71 YRS m NR NO NR 4 NA NO ABCIXIMAB CATHETER CARDIOVASC INTERV 49:177-180 2000 56 YRS F YES YES 3 4 NA NO ABCIXIMAB AM HEART J 140:74 2000 NR NR NR NO NR 5 1 NO ABCIXIMAB CATHETER CARDIOVASC INTERV 52:468 2001 75 YRS F NO YES 0 3 NA NO ABCIXIMAB HAEMATOLOGICA 86:E07 2001 82 YRS M NO YES 0 3 NA NO ABCIXIMAB J INVASIVE CARDIOL 13:56 2001 52 YRS F NR NO NR 3 NA NO ABCIXIMAB CARDIOLOGY 95:215-216 2001 55 YRS M NR NO NR 4 NA NO ABCIXIMAB CARDIOLOGY 95:215-216 2001 51 YRS M NR NO NR 4 NA NO ABCIXIMAB HEART 86:E18 2001 68 YRS M YES NO 2 4 NA NO ABCIXIMAB J INV CARDIO 13:56-8 2001 52 YRS F NO NO 0 4 NA NO ABCIXIMAB CATH & CARDIOVASC INTERV 53:225-8 2001 NR NR NR NR NR 5 2 NO ABCIXIMAB NEJM 344:1888-1894 2001 NR NR NR NO NR 5 1 NO ABCIXIMAB J CARDIOVASC PHARMACOL THER 7:21-24 2002 65 YRS F NO YES 1 2 NA NO ABCIXIMAB QJ MED 95:635-638 2002 55 YRS M NO YES 1 3 NA NO ABCIXIMAB J INVASIVE CARDIOL 16: 537-538 2004 75 YRS M NO YES NR 1 NA NO ABCIXIMAB HEART 90:E55 2004 44 YRS F NO YES 3 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 71 YRS M NR YES 1 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 71 YRS F NR YES 1 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 72 YRS M NR YES 3 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 72 YRS M NR NO 1 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 55 YRS M NR YES 0 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 60 YRS F NR YES 1 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 61 YRS M NR YES 0 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 67 YRS F NR YES 2 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 79 YRS M NR YES 1 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 67 YRS F NR YES 3 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 57 YRS M NR YES 3 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 63 YRS M NR YES 2 3 NA NO ABCIXIMAB J THROMB HAEMOST 2:985-992 2004 74 YRS F NR YES 0 3 NA NO DRUG NAME CITATION YEAR AGE SEX DEATH HOS BL SC EX NEW 2018 ABCIXIMAB ITAL HEART J 6:647-651 2005 53 YRS M NO YES 0 3 NA NO ABCIXIMAB ITAL HEART J 6:647-651 2005 47 YRS M NO YES 0 3 NA NO ABCIXIMAB J INVASIVE CARDIOL 18: E173-E174 2006 43 YRS M NR YES 3 5 1 NO ABCIXIMAB PHARMACOTHERAPY 26:423-427 2006 62 YRS M NR NO NR 5 1 NO ABCIXIMAB J THROMB THROMBOLYSIS 24:59-64 2007 59 YRS M NR YES 0 2 NA NO ABCIXIMAB J THROMB THROMBOLYSIS 24:59-64 2007 51 YRS M NO YES 0 3 NA NO ABCIXIMAB J INTERV CARDIOL 21:100-5 2008 64 YRS M NO YES 3 2 NA NO ABCIXIMAB THROMB HAEMOST 103:484-6 2010 NR NR NR NR NR 5 1 NO ABCIXIMAB PLATELETS 22:302-4 2011 77 YRS M NO YES NR 3 NA NO ACECLOFENAC INT J DERMATOL 54:819-22 2015 44 YRS F NO NR NR 1 NA YES ACETAMINOPHEN BMJ 3:743-374 1968 63 YRS F NO NO 1 1 NA NO ACETAMINOPHEN NEJM 287:376-381 1972 22 YRS M NR YES NR 3 NA NO ACETAMINOPHEN CLEVE CLIN Q 40: 89-91 1973 61 YRS M NO YES 3 2 NA NO ACETAMINOPHEN LANCET 2:1159 1978 30 YRS M NO YES 2 1 NA NO ACETAMINOPHEN NEJM 300:678 1979 29 YRS M NR NO NR 3 NA NO ACETAMINOPHEN NEJM 303:47 1980 70 YRS M NO NO 1 1 NA NO ACETAMINOPHEN ANN INTERN MED 95:783 1981 80 YRS M NO YES 3 2 NA NO ACETAMINOPHEN BLOOD 97:3846 2001 66 YRS F NR NO NR 2 NA NO ACETAMINOPHEN BLOOD 97:3846 2001 30 YRS M NR NO NR 2 NA NO ACETAMINOPHEN BLOOD 109:3608-9 2007 4 YRS F NO YES 2 1 NA NO ACETAZOLAMIDE JAMA 160:206-207 1956 85 YRS M NO YES 3 2 NA NO ACETAZOLAMIDE ARCH INTERN MED 99:1006 1957 61 YRS M NO NO NR 2 NA NO ACETAZOLAMIDE ARCH INTERN MED 99:1000 1957 61 YRS M NR YES NR 4 NA NO ACETAZOLAMIDE BMJ 1:1338 1958 69 YRS F NR NR NR 4 NA NO ACETAZOLAMIDE AM J OPHTHALMOL 100:79-81 1985 NR NR NR NO NR 5 1 NO ACETAZOLAMIDE ARCH OPHTHALMOL 122:1543-1544 2004 67 YRS M NO YES 0 1 NA NO ACTINOMYCIN D AM J THER 23:E594-6 2016 3.5 YRS F NO YES NR 5 3 YES ACYCLOVIR AM J EMERG MED 16:396-398 1998 8 YRS M NR NO NR 5 2 NO ACYCLOVIR PHARMACOTHERAPY 30:1089-93 2010 20 YRS M NO YES 0 2 NA NO ADALIMUMAB GUT 56:1169-70 2007 42 YRS F NO NO 0 3 NA NO ADALIMUMAB J CROHNS COLITIS 6:1034-7 2012 71 YRS F NR NR NR 4 NA NO ADALIMUMAB INT J PHARM PHARM SCI 7:456-8 2015 26 YRS M NO YES 1 2 NA YES ADEFOVIR DIG LIVER DIS 38:211-212 2006 56 YRS M NO YES NR 1 NA NO DRUG NAME CITATION YEAR AGE SEX DEATH HOS BL SC EX NEW 2018 AGOMELATINE THERAPIE 72:401-2 2017 60 YRS F YES NR 2 3 NA YES ALATROFLOXACIN ANN PHARMACOTHER 34:330 2000 54 YRS F NO YES 2 2 NA NO ALBENDAZOLE ANN PHARMACOTHER 32:842 1998 25 YRS F NO YES 2 2 NA NO ALFUZOSIN ARCH ITAL UROL ANDROL 82:195-7 2010 65 YRS M NO NO 0 1 NA NO ALLOPURINOL MED J AUST 2:468 1973 86 YRS F NR NO NR 5 1 NO ALLOPURINOL JAMA 227:1036 1974 NR NR NR NO NR 5 1 NO ALLOPURINOL DICP 15:286-287 1981 NR NR NR NO NR 5 2 NO ALPRENOLOL ACTA MED SCAND 207:231-233 1980 65 YRS F NO YES 2 1 NA NO AMINOGLUTETHIMIDE CANCER TREATMENT REPORTS 66:1785-1786 1982 58 YRS F NO YES 0 1 NA NO AMINOGLUTETHIMIDE CANCER TREATMENT REPORTS 67:849 1983 47 YRS F NR YES NR 4 NA NO AMINOGLUTETHIMIDE CANCER TREATMENT REPORTS 68:1015-1016 1984 53 YRS F NO YES 3 1 NA NO AMINOGLUTETHIMIDE CONN MED 48:423-424 1984 63 YRS F NO NO 2 2 NA NO AMINOGLUTETHIMIDE TUMORI 76:511-512 1990 49 YRS F NR YES NR 3 NA NO AMINOSALICYLIC ACID JAMA 153:1094 1953 18 YRS F NO NO 3 1 NA NO AMINOSALICYLIC ACID DIS CHEST 23:645-656 1953 49 YRS M NO YES 0 3 NA NO AMINOSALICYLIC ACID JAMA 172:1909 1960 63 YRS M NO YES 2 1 NA NO AMINOSALICYLIC ACID AM J MED 53:790-796 1972 45 YRS M NO YES 1 2 NA NO AMINOSALICYLIC ACID J PEDIATR 83:502-503 1973 8 MOS M NO YES 2 1 NA NO AMIODARONE ARCH INTERN MED 147:735-736 1987 45 YRS M NO YES 1 1 NA NO AMIODARONE ARCH INTERN MED 147:735-736 1987 69 YRS M NO YES 1 1 NA NO AMIODARONE BR J HAEMATOL 163: 260-7 2013 NR NR NR NR NR 3 NA NO AMIODARONE BR.
Recommended publications
  • Wo 2009/081169 A2

    Wo 2009/081169 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation

    Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation

    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste

    NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste

    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Page 1 Note: Within Nine Months from the Publication of the Mention

    Page 1 Note: Within Nine Months from the Publication of the Mention

    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
  • ACR Manual on Contrast Media

    ACR Manual on Contrast Media

    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
  • Ep 0119020 A2

    Ep 0119020 A2

    European Patent Office © Publication number: 0 119 020 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 84300949.9 © Int. CI.3: A 61 K 9/50 © Date of filing: 14.02.84 © © Priority: 15.02.83 GB 8304165 Inventor: Ridgway, Frank 03.10.83 GB 8326448 Bellefield Noctorum Lane 06 01 84 GB 8400306 Noctorum Birkenhead Merseyside(GB) © Inventor: Payne, Nicholas 1. ©Date of publication of application: SAntoiw Road P«^r 19.09.84 Bulletin 84138 W.rral Merseyside(GB) © Inventor: © Designated Contracting States: Timmins, Peter AT BE CH DE FR GB FT LI LU NL SE 34ThornleyRoadMoreton Wirral Merseyside(GB) © Applicant: E.R. Squibb & Sons, Inc. c\ , _ „t Uwrenceville-Princeton Road ® '"v.f nt°I: Groom/ Ch?f Vanessa Princeton. N.J. 08540{US) 1 West Cottages Leadpipe Lane Cotherstone Barnard Castle County Durham(GB) © Representative: Thomas, Roger Tamlyn et al, D. Young & Co. 10 Staple Inn London WC1V7RD(GB) (54) Method of preparing liposomes and products produced thereby. ©A A method is provided for preparing a stable liposome precursors in the form of a particulate carrier materials coated with thin films of liposome components, which method includes the steps of dissolving at least one liposome-forming amphipathic lipid, optionally, at least one biologically active compound, and, optionally, at least one adjuvant in a suitable solvent and employing the resulting solution to coat a suitable particulate carrier material which is substantially insoluble in the above-mentioned solvent, to form thin films of liposome components thereon. Upon exposing the coated carrier material to water, the thin films of liposome components hydrate.
  • ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / I

    ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / I

    ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / i ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media © Copyright 2013 American College of Radiology ISBN: 978-1-55903-012-0 Table of Contents Topic Last Updated Page 1. Preface. V9 – 2013 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection And Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation Of Contrast Media . V7 – 2010 . 17 6. Allergic-Like And Physiologic Reactions To Intravascular Iodinated Contrast Media . V9 – 2013 . 21 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media In Children . V7 – 2010 . 47 11. Gastrointestinal (GI) Contrast Media In Adults: Indications And Guidelines V9 – 2013 . 55 12. Adverse Reactions To Gadolinium-Based Contrast Media . V7 – 2010 . 77 13. Nephrogenic Systemic Fibrosis . V8 – 2012 . 81 14. Treatment Of Contrast Reactions . V9 – 2013 . 91 15. Administration Of Contrast Media To Pregnant Or Potentially Pregnant Patients . V9 – 2013 . 93 16. Administration Of Contrast Media To Women Who Are Breast-Feeding . V9 – 2013 . 97 Table 1 – Indications for Use of Iodinated Contrast Media . V9 – 2013 . 99 Table 2 – Organ and System-Specific Adverse Effects from the Administration of Iodine-Based or Gadolinium-Based Contrast Agents. V9 – 2013 . 100 Table 3 – Categories of Acute Reactions . V9 – 2013 . 101 Table 4 – Treatment of Acute Reactions to Contrast Media in Children . V9 – 2013 .
  • Update on Ionis Pharmaceuticals June 7, 2016

    Update on Ionis Pharmaceuticals June 7, 2016

    Update on Ionis Pharmaceuticals June 7, 2016 Due to recent announcements and ongoing price weakness in the stock of Ionis Pharmaceuticals, we wanted to provide you an update on our thinking relating to your investment in the company. Background: Buena Vista Investment Management began investing in Ionis Pharmaceuticals (previously known as Isis Pharmaceuticals) in 2004 based on our belief that their genetic research and unique approach to discovering new drugs through the use of Antisense Technology would eventually lead to a much higher stock price. Since that first investment 12 years ago we have seen many ups and downs in the stock price but through it all the company’s technology continues to improve and its balance sheet has never been better. As investors, we entered 2016 with the potential for a lot of good news. First, the company had three phase 3 trials coming to endpoints within 18 months. Second, the company’s new subsidiary, Akcea Therapeutics, which was created to focus on their lipid franchise, was now up and running. The company had an exceptionally strong balance sheet for a biotechnology company, with approximately $700 million in cash and marketable securities. And most importantly, the company now had 38 compounds in clinical trials, an unheard of number for a company of this size. Yet with all of these potential positive catalysts for the stock, we are now sitting at the same price level as we were in the beginning of 2014. The price of Ionis stock has dropped from a high of $77 per share in April of 2015 to the mid 20’s today.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • The International Pharmacopoeia

    The International Pharmacopoeia

    The International Pharmacopoeia THIRD EDITION Pharmacopoea internationalis Editio tertia Volume 4 Tests, methods, and general requirements Quality specifications for pharmaceutical substances, excipients, and dosage forms World Health Organization Geneva 1994 WHO Library Cataloguing in Publication Data The International Pharmacopoeia.- 3rd ed. Contents: v. 4. Tests, methods, and general requirements 1. Drugs -analysis 2. Drugs -standards ISBN 92 4 154462 7 (NLM Classification: QV 25) The World Health Organization welcomes requests for permission to reproduce or translate its publica- tions, in part or in full. Applications and enquiries should be addressed to the Of£ice of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. O World Health Organization, 1994 Publications of the World Health Organization enjoy copyright protection in accordance with the provi- sions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters.